REG - Oxford Biomedica PLC - Board Change

Oxford BioMedicaAnnouncement

20/10/2025 10:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251020:nRST0318Ea&default-theme=true

RNS Number : 0318E  Oxford Biomedica PLC  20 October 2025

 

 

Board Change

 

·      Robert Ghenchev, Non-Executive Director, has stepped down from
the Board following his departure from Novo Holdings US

 

Oxford, UK - 20 October 2025: OXB (LSE: OXB), a global quality and
innovation-led cell and gene therapy CDMO, today announces that Robert
Ghenchev, Non-Executive Director, has stepped down from the OXB Board with
immediate effect, following his departure from Novo Holdings US to pursue
other opportunities.

 

Robert Ghenchev, outgoing Non-Executive Director of OXB, stated: "It has been
a pleasure to serve on the Board of OXB, during which time the Company has
made strong progress in executing its strategy and strengthening its position
as a leading global pure-play cell and gene therapy CDMO. I have great
confidence in the Company's leadership and wish the Board and wider team every
success for the future."

 

Dr. Roch Doliveux, Chair of OXB, commented: "On behalf of the Board, I would
like to take this opportunity to thank Rob for his excellent contributions to
the Board over the past six years, a period of significant transformation for
OXB, and wish him the very best for his future."

 

Novo Holdings A/S, a major shareholder in OXB, has reserved the right to
nominate another person to be a shareholder Director, subject to the approval
of OXB's Board of Directors. OXB will provide any further update to the market
in due course, as appropriate.

 

 

-Ends-

 

Enquiries:

OXB:

T: +44 (0) 1865 509 737 / E: ir@oxb.com (mailto:ir@oxb.com)

Sophia Bolhassan, Head of Investor Relations

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the TetraVecta™
system), a dual-plasmid system for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It
has development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com
(http://www.oxb.com) and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPKKBDCBDKAKB



            Copyright 2019 Regulatory News Service, all rights reserved